Undisclosed: Actual infant deaths following injection of RSV antibodies
In the light of the accumulating red flags,omissions and suppressed signals now coming to light, it is no longer tenable for either product to remain immune from scrutiny.
Published on 7 October 2025 by pgibertie
Both nirsevimab (Beyfortus) and clesrovimab deserve a thorough re-evaluation by ACIP – this time with full data on the table.
As ACIP deliberated without access to the full trial data, an even more alarming pattern was already emerging in the real world. Today, analysis of the FDA’s FAERS database reveals 37 infant deaths out of just 991 reports, a mortality rate almost twice that of other routine vaccines.
Why has this information not been disclosed?
The alarm bells were already ringing in the clinical trials: infant deaths in the treatment groups were twice as frequent as in the control groups – a signal that should have triggered an immediate review.
As a previous Brownstone article shows, this alarming imbalance was not revealed to ACIP during the June 2025 review of Merck’s rival RSV antibody, Clesrovimab. It now appears that this was not the only red flag that was hidden from the committee.
An analysis of actual data from the FDA’s Adverse Event Reporting System (FAERS) reveals an even grimmer reality: since Sanofi’s Beyfortus (nirsevimab) was approved and added to the US infant vaccination schedule in 2023, there have been 1,012 adverse event reports – including 37 infant deaths, a concentration rarely seen in paediatric vaccine safety profiles.
https://brownstone.org/articles/withheld-real-world-infant-deaths-from-rsv-antibody-shot
